Difference between revisions of "Osteosarcoma - null regimens"
Jump to navigation
Jump to search
(Created page with "The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight in...") |
m |
||
(22 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
− | The purpose of this page is to provide references to "null therapy" such as placebo and observation. | + | The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the [[Osteosarcoma|main osteosarcoma page]] for regimens that include active anticancer treatment. |
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
Line 5: | Line 5: | ||
==Observation== | ==Observation== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
===Regimen=== | ===Regimen=== | ||
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
− | !style="width: 20%"| | + | !style="width: 20%"|Dates of enrollment |
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 20%"|Comparator | !style="width: 20%"|Comparator | ||
Line 25: | Line 22: | ||
|} | |} | ||
''No further treatment.'' | ''No further treatment.'' | ||
+ | <div class="toccolours" style="background-color:#cbd5e8"> | ||
====Preceding treatment==== | ====Preceding treatment==== | ||
− | *[[Osteosarcoma#M-BCD| | + | *Neoadjuvant [[Osteosarcoma#M-BCD|M-BCD]], then [[Surgery#Surgical_resection|surgery]], with good response |
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol. 1987 Jan;5(1):21-6. [https://doi.org/10.1200/JCO.1987.5.1.21 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3543236 PubMed] | + | # Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol. 1987 Jan;5(1):21-6. [https://doi.org/10.1200/JCO.1987.5.1.21 link to original article] [https://pubmed.ncbi.nlm.nih.gov/3543236/ PubMed] |
− | ## '''Update:''' Bernthal NM, Federman N, Eilber FR, Nelson SD, Eckardt JJ, Eilber FC, Tap WD. Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. Cancer. 2012 Dec 1;118(23):5888-93. Epub 2012 May 30. [https:// | + | ## '''Update:''' Bernthal NM, Federman N, Eilber FR, Nelson SD, Eckardt JJ, Eilber FC, Tap WD. Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. Cancer. 2012 Dec 1;118(23):5888-93. Epub 2012 May 30. [https://doi.org/10.1002/cncr.27651 link to original article] [https://pubmed.ncbi.nlm.nih.gov/22648705/ PubMed] |
=Maintenance after upfront therapy= | =Maintenance after upfront therapy= | ||
==Observation== | ==Observation== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
===Regimen=== | ===Regimen=== | ||
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
− | !style="width: 20%"| | + | !style="width: 20%"|Dates of enrollment |
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 20%"|Comparator | !style="width: 20%"|Comparator | ||
Line 48: | Line 44: | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486345/ Bielack et al. 2015 (EURAMOS-1 good response)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486345/ Bielack et al. 2015 (EURAMOS-1 good response)] | ||
|2005-2011 | |2005-2011 | ||
− | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
− | |Interferon alfa- | + | |[[#Interferon_alfa-2b_monotherapy_999|Interferon alfa-2b]] |
| style="background-color:#ffffbf" |Did not meet primary endpoint of EFS | | style="background-color:#ffffbf" |Did not meet primary endpoint of EFS | ||
|- | |- | ||
|} | |} | ||
''No further treatment.'' | ''No further treatment.'' | ||
+ | <div class="toccolours" style="background-color:#cbd5e8"> | ||
====Preceding treatment==== | ====Preceding treatment==== | ||
− | *[[Osteosarcoma#MAP| | + | *Neoadjuvant [[Osteosarcoma#MAP|MAP]] x 2, then [[Surgery#Surgical_resection|surgery]], then adjuvant [[Osteosarcoma#MAP_2|MAP]] x 2, then adjuvant [[Osteosarcoma#MA_2|MA]] x 2 |
+ | </div></div> | ||
+ | ===References=== | ||
+ | # '''EURAMOS-1 good response:''' Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Letson GD, Teot LA, Goorin A, Baumhoer D, Kager L, Werner M, Lau CC, Sundby Hall K, Gelderblom H, Meyers P, Gorlick R, Windhager R, Helmke K, Eriksson M, Hoogerbrugge PM, Schomberg P, Tunn PU, Kühne T, Jürgens H, van den Berg H, Böhling T, Picton S, Renard M, Reichardt P, Gerss J, Butterfass-Bahloul T, Morris C, Hogendoorn PC, Seddon B, Calaminus G, Michelagnoli M, Dhooge C, Sydes MR, Bernstein M; EURAMOS-1 investigators. Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative map: first results of the EURAMOS-1 good response randomized controlled trial. J Clin Oncol. 2015 Jul 10;33(20):2279-87. Epub 2015 Jun 1. [https://doi.org/10.1200/JCO.2014.60.0734 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486345/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26033801/ PubMed] | ||
+ | |||
+ | =Relapsed, refractory, or metastatic, subsequent lines= | ||
+ | ==Placebo== | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | !style="width: 20%"|Study | ||
+ | !style="width: 20%"|Dates of enrollment | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 20%"|Comparator | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7799443/ Davis et al. 2019 (SARC024)] | ||
+ | |2014-2018 | ||
+ | | style="background-color:#1a9851" |Randomized Phase 2 (C) | ||
+ | |[[Osteosarcoma#Regorafenib_monotherapy|Regorafenib]] | ||
+ | | style="background-color:#d73027" |Inferior PFS | ||
+ | |- | ||
+ | |} | ||
+ | ''No active antineoplastic treatment.'' | ||
+ | </div> | ||
===References=== | ===References=== | ||
− | # ''' | + | #'''SARC024:''' Davis LE, Bolejack V, Ryan CW, Ganjoo KN, Loggers ET, Chawla S, Agulnik M, Livingston MB, Reed D, Keedy V, Rushing D, Okuno S, Reinke DK, Riedel RF, Attia S, Mascarenhas L, Maki RG. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. J Clin Oncol. 2019 Jun 1;37(16):1424-1431. Epub 2019 Apr 23. [https://doi.org/10.1200/jco.18.02374 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7799443/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/31013172/ PubMed] [https://clinicaltrials.gov/study/NCT02048371 NCT02048371] |
[[Category:Osteosarcoma regimens]] | [[Category:Osteosarcoma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Bone sarcomas]] | [[Category:Bone sarcomas]] | ||
− | |||
[[Category:Null regimens]] | [[Category:Null regimens]] | ||
+ | [[Category:Pediatric solid tumors]] |
Latest revision as of 17:31, 14 April 2024
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main osteosarcoma page for regimens that include active anticancer treatment.
Adjuvant therapy
Observation
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Eilber et al. 1987 | 1981-1984 | Randomized (C) | M-BCD | Seems to have inferior OS |
No further treatment.
References
- Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol. 1987 Jan;5(1):21-6. link to original article PubMed
- Update: Bernthal NM, Federman N, Eilber FR, Nelson SD, Eckardt JJ, Eilber FC, Tap WD. Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. Cancer. 2012 Dec 1;118(23):5888-93. Epub 2012 May 30. link to original article PubMed
Maintenance after upfront therapy
Observation
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Bielack et al. 2015 (EURAMOS-1 good response) | 2005-2011 | Phase 3 (C) | Interferon alfa-2b | Did not meet primary endpoint of EFS |
No further treatment.
References
- EURAMOS-1 good response: Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Letson GD, Teot LA, Goorin A, Baumhoer D, Kager L, Werner M, Lau CC, Sundby Hall K, Gelderblom H, Meyers P, Gorlick R, Windhager R, Helmke K, Eriksson M, Hoogerbrugge PM, Schomberg P, Tunn PU, Kühne T, Jürgens H, van den Berg H, Böhling T, Picton S, Renard M, Reichardt P, Gerss J, Butterfass-Bahloul T, Morris C, Hogendoorn PC, Seddon B, Calaminus G, Michelagnoli M, Dhooge C, Sydes MR, Bernstein M; EURAMOS-1 investigators. Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative map: first results of the EURAMOS-1 good response randomized controlled trial. J Clin Oncol. 2015 Jul 10;33(20):2279-87. Epub 2015 Jun 1. link to original article link to PMC article PubMed
Relapsed, refractory, or metastatic, subsequent lines
Placebo
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Davis et al. 2019 (SARC024) | 2014-2018 | Randomized Phase 2 (C) | Regorafenib | Inferior PFS |
No active antineoplastic treatment.
References
- SARC024: Davis LE, Bolejack V, Ryan CW, Ganjoo KN, Loggers ET, Chawla S, Agulnik M, Livingston MB, Reed D, Keedy V, Rushing D, Okuno S, Reinke DK, Riedel RF, Attia S, Mascarenhas L, Maki RG. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. J Clin Oncol. 2019 Jun 1;37(16):1424-1431. Epub 2019 Apr 23. link to original article link to PMC article PubMed NCT02048371